Home › Entities › clinical_trial › Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

clinical trial
MedicalStudy clinical_trial Q64802853
Press Enter · cited answer in seconds

Summary

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study is a clinical trial[1].

Key Facts

  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study is in the country of a Validation Study — country (P17): United States[2].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's instance of is recorded as a Validation Study — instance of (P31): clinical trial[3].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's start time is recorded as +2018-05-30T00:00:00Z[4].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's end time is recorded as +2019-03-20T00:00:00Z[5].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's sponsor is recorded as a Validation Study — sponsor (P859): University of Florida[6].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's main subject is recorded as a Validation Study — main subject (P921): clopidogrel[7].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's main subject is recorded as a Validation Study — main subject (P921): coronary artery disease[8].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's number of participants is recorded as {'unit': '1', 'amount': '+14'}[9].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's title is recorded as Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease[10].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's ClinicalTrials.gov ID is recorded as NCT03489863[12].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}[13].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's research intervention is recorded as a Validation Study — research intervention (P4844): prasugrel hydrochloride[14].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's clinical trial phase is recorded as a Validation Study — clinical trial phase (P6099): phase IV clinical trial[15].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's research site is recorded as a Validation Study — research site (P6153): University of Florida[16].
  • Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study's study type is recorded as a Validation Study — study type (P8363): interventional study[17].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study. Retrieved May 3, 2026, from https://4ort.xyz/entity/prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study
MLA “Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study.
BibTeX @misc{4ortxyz_prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study}}, year = {2026}, url = {https://4ort.xyz/entity/prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study — https://4ort.xyz/entity/prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/prasugrel-versus-ticagrelor-in-patients-with-cyp2c19-loss-of-function-a-validation-study · Last refreshed: